Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Glycosaminoglycan (GAG) degradation enzymes are a group of lysosomal hydrolases and lyases responsible for the stepwise breakdown of glycosaminoglycans—long, linear, negatively charged polysaccharides found in the extracellular matrix and on cell surfaces. GAGs include heparan sulfate, heparin, chondroitin sulfate, dermatan sulfate, keratan sulfate, and hyaluronan. These enzymes are essential for normal cellular turnover of GAGs and play critical roles in tissue remodeling, signaling regulation, and homeostasis. Degradation primarily occurs in lysosomes after endocytosis or phagocytosis of proteoglycans/GAGs. Inherited defects in these enzymes result in mucopolysaccharidoses—a group of lysosomal storage disorders characterized by accumulation of undegraded GAG fragments. Understanding these enzymes' activity is vital not only for basic biology but also for therapeutic strategies targeting lysosomal storage diseases or modulating tissue repair/regeneration through controlled ECM remodeling.
Hydrolytic or eliminative cleavage of glycosaminoglycans
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Glycosaminoglycan Degradation Enzymes.